Evidence map›Paper›PMID 38422166›Full record

ArticlePLoS biology2024

Ebola virus VP35 interacts non-covalently with ubiquitin chains to promote viral replication.

Carlos A Rodríguez-Salazar, Sarah van Tol, Olivier Mailhot, Maria Gonzalez-Orozco, Gabriel T Galdino, Abbey N Warren, Natalia Teruel, Padmanava Behera, Kazi Sabrina Afreen, Lihong Zhang and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. 25 Years of Ebola Virus VP35 Research.Journal of molecular biology · 2025
    Review
  7. Article
  8. Review
  9. Unconventional posttranslational modification in innate immunity.Cellular and molecular life sciences : CMLS · 2024
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Carlos A Rodríguez-SalazarDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Sarah van TolDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Olivier MailhotDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Maria Gonzalez-OrozcoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Gabriel T GaldinoDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Abbey N WarrenDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Natalia TeruelDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Padmanava BeheraCenter for Virus-Host-Innate Immunity and Department of Medicine; Rutgers Biomedical and Health Sciences, Institute for Infectious and Inflammatory Diseases, Rutgers University, Newark, New Jersey, United States of America.
Kazi Sabrina AfreenCenter for Virus-Host-Innate Immunity and Department of Medicine; Rutgers Biomedical and Health Sciences, Institute for Infectious and Inflammatory Diseases, Rutgers University, Newark, New Jersey, United States of America.
Lihong ZhangDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Terry L JuelichDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Jennifer K SmithDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
María Inés ZylberDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Alexander N FreibergDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Rafael J NajmanovichDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
Maria I GiraldoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.ORCID 0000-0002-5058-5444
The University of Texas Medical Branch at Galveston · USUniversité de Montréal · CARutgers, The State University of New Jersey · USCorporación Universitaria Empresarial Alexander von Humboldt · CO

Funding

Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2021 to 2025
$11.3M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
The Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6M
The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced PathologyR01AI155466 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Ricardo Rajsbaum · 2021 to 2026
$2.5M
NIAID NIH HHS P01 AI150585NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI155466NIAID NIH HHS R01 AI166668NIAID NIH HHS T32 AI060549
6 · The paper itself

Abstract

Ebolavirus (EBOV) belongs to a family of highly pathogenic viruses that cause severe hemorrhagic fever in humans. EBOV replication requires the activity of the viral polymerase complex, which includes the cofactor and Interferon antagonist VP35. We previously showed that the covalent ubiquitination of VP35 promotes virus replication by regulating interactions with the polymerase complex. In addition, VP35 can also interact non-covalently with ubiquitin (Ub); however, the function of this interaction is unknown. Here, we report that VP35 interacts with free (unanchored) K63-linked polyUb chains. Ectopic expression of Isopeptidase T (USP5), which is known to degrade unanchored polyUb chains, reduced VP35 association with Ub and correlated with diminished polymerase activity in a minigenome assay. Using computational methods, we modeled the VP35-Ub non-covalent interacting complex, identified the VP35-Ub interacting surface, and tested mutations to validate the interface. Docking simulations identified chemical compounds that can block VP35-Ub interactions leading to reduced viral polymerase activity. Treatment with the compounds reduced replication of infectious EBOV in cells and in vivo in a mouse model. In conclusion, we identified a novel role of unanchored polyUb in regulating Ebola virus polymerase function and discovered compounds that have promising anti-Ebola virus activity.

Indexed as

EbolavirusHemorrhagic Fever, EbolaNucleocapsid ProteinsUbiquitinVirus ReplicationAnimalsHumansMiceViral Regulatory and Accessory ProteinsNucleocapsid Proteinsnucleoprotein VP35, Ebola virusUbiquitinViral Regulatory and Accessory Proteins

Identifiers

PMID38422166
PMCPMC10942258
OpenAlexW4392283093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.